NEW YORK, Sept. 12, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of purchasers of the securities of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) (the “Company”) from August 2, 2017 through September 11, 2017, both dates inclusive (the “Class Period”).
Investors who have incurred losses in Health Insurance Innovations, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you have purchased shares of Health Insurance Innovations, Inc. and would like to assist with the litigation process as a lead plaintiff, you may, no later than November 13, 2017, request that the Court appoint you lead plaintiff of the proposed class.
According to the filed complaint, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Health Insurance Innovations’ application for a third-party insurance administrators license with the Florida Office of Insurance Regulation was denied due in part to material errors and omissions;
- the Florida Office of Insurance Regulation’s rejection of Health Insurance Innovations’ application for a third-party insurance administrators license could result in its losing licenses in the other states; and
- as a result, Health Insurance Innovations’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
On September 11, 2017, an article was published on SeekingAlpha.com alleging that in June 2017 one of Health Insurance Innovations' key license applications was rejected after regulators uncovered undisclosed legal actions against Company insiders; and that the Company privately warned a Florida regulator that a rejection of its license application could create a "domino effect" whereby licensing denials would spread to the other states.
On this news, Health Insurance Innovations' share price fell $6.55, or 21.91%, to close at $23.35 on September 11, 2017. The stock continued to plummet on September 12th, trading as low as $18.70 per share intraday, an additional decline of 20%.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 



